Am J Psychiatry 162:947-953, May 2005
© 2005 American Psychiatric Association
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Nina Schooler, Ph.D.,
Jonathan Rabinowitz, Ph.D.,
Michael Davidson, M.D.,
Robin Emsley, M.D.,
Philip D. Harvey, Ph.D.,
Lili Kopala, M.D.,
Patrick D. McGorry, M.D.,
Ilse Van Hove, M.Sc.,
Marielle Eerdekens, M.D.,
Wim Swyzen, M.D., and
Goedele De Smedt, M.D.
the Early Psychosis Global Working Group
OBJECTIVE: The first episode of psychotic illness is a key intervention point. The initial experience with medication can affect willingness to accept treatment. Further, relapse prevention is a treatment cornerstone during the first years of illness because active psychotic illness may affect lifetime outcomes. Thus, initial treatment of active symptoms and subsequent relapse prevention are central goals of pharmacotherapy. This study compared long-term effectiveness of risperidone versus haloperidol in first-episode psychosis patients. METHOD: First-episode psychosis patients (N=555, mean age=25.4 years) participated in a double-blind, randomized, controlled flexible-dose trial that compared risperidone (mean modal dose=3.3 mg) and haloperidol (mean modal dose=2.9 mg). The median treatment length was 206 days (maximum=1,514). RESULTS: Positive and Negative Syndrome Scale scores and Clinical Global Impression ratings improved significantly relative to baseline, with no significant differences between groups. Three-quarters of the patients achieved initial clinical improvement, defined as >20% reduction in total Positive and Negative Syndrome Scale score. However, among those who achieved clinical improvement, 42% of the risperidone group experienced a relapse compared with 55% of the haloperidol group. The median time to relapse was 466 days for risperidone-treated subjects and 205 days for those given haloperidol. These differences were statistically significant based on Kaplan-Meier survival analysis. Adverse effects distinguished the treatments: there were significantly more extrapyramidal signs and symptoms and adjunctive medication use in the haloperidol group and greater prolactin elevation in the risperidone group. There was less weight gain with haloperidol initially but no significant differences between groups at endpoint. CONCLUSIONS: Relatively low doses of antipsychotic drugs lead to significant symptom amelioration in the majority of first-episode psychosis patients. In the long term, risperidone prevents relapse in more patients and for a longer time and also induces less abnormal movements than haloperidol.
This article has been cited by other articles:
|
|
|
|
 
J. de Leon, N. B. Sandson, and K. L. Cozza
A Preliminary Attempt to Personalize Risperidone Dosing Using Drug-Drug Interactions and Genetics: Part II
Psychosomatics,
July 1, 2008;
49(4):
347 - 361.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.A. Rosenheck, D.L. Leslie, S. Busch, E. S. Rofman, and M. Sernyak
Rethinking Antipsychotic Formulary Policy
Schizophr Bull,
March 1, 2008;
34(2):
375 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rabinowitz and O. Davidov
The Association of Dropout and Outcome in Trials of Antipsychotic Medication and Its Implications for Dealing With Missing Data
Schizophr Bull,
March 1, 2008;
34(2):
286 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Leucht, S. Heres, J. Hamann, and J. M. Kane
Methodological Issues in Current Antipsychotic Drug Trials
Schizophr Bull,
March 1, 2008;
34(2):
275 - 285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bushe, M. Shaw, and R. C Peveler
A review of the association between antipsychotic use and hyperprolactinaemia
J Psychopharmacol,
March 1, 2008;
22(2_suppl):
46 - 55.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Bushe, D. Yeomans, T. Floyd, and S. M Smith
Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics
J Psychopharmacol,
March 1, 2008;
22(2_suppl):
56 - 62.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Lewis and J. Lieberman
CATIE and CUtLASS: can we handle the truth?
The British Journal of Psychiatry,
March 1, 2008;
192(3):
161 - 163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rabinowitz, S. Z. Levine, O. Barkai, and O. Davidov
Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features
Schizophr Bull,
February 26, 2008;
(2008)
sbn005v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Bibliography Schizophrenia
Focus,
January 1, 2008;
6(2):
197 - 199.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Rossi, U. Balottin, M. Rossi, M. Chiappedi, E. Fazzi, and G. Lanzi
Pharmacological Treatment of Anorexia Nervosa: A Retrospective Study in Preadolescents and Adolescents
Clinical Pediatrics,
December 1, 2007;
46(9):
806 - 811.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. A. Rosenheck
Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics
The British Journal of Psychiatry,
September 1, 2007;
191(3):
238 - 245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. McEvoy, J. A. Lieberman, D. O. Perkins, R. M. Hamer, H. Gu, A. Lazarus, D. Sweitzer, C. Olexy, P. Weiden, and S. D. Strakowski
Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week Comparison
Am J Psychiatry,
July 1, 2007;
164(7):
1050 - 1060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L Bettinger, G. Shuler, D. R Jones, and J. P Wilson
Schizophrenia: Multi-Attribute Utility Theory Approach to Selection of Atypical Antipsychotics
Ann. Pharmacother.,
February 1, 2007;
41(2):
201 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Robinson, M. G. Woerner, B. Napolitano, R. C. Patel, S. M. Sevy, H. Gunduz-Bruce, J. M. Soto-Perello, A. Mendelowitz, A. Khadivi, R. Miller, et al.
Randomized Comparison of Olanzapine Versus Risperidone for the Treatment of First-Episode Schizophrenia: 4-Month Outcomes
Am J Psychiatry,
December 1, 2006;
163(12):
2096 - 2102.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S Turner and D. W Stewart
Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
J Psychopharmacol,
November 1, 2006;
20(6 Suppl):
20 - 37.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. A. Lieberman
Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
Arch Gen Psychiatry,
October 1, 2006;
63(10):
1069 - 1072.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rabinowitz, P. D. Harvey, M. Eerdekens, and M. Davidson
Premorbid functioning and treatment response in recent-onset schizophrenia
The British Journal of Psychiatry,
July 1, 2006;
189(1):
31 - 35.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Bola
Psychosocial Acute Treatment in Early-Episode Schizophrenia Disorders
Research on Social Work Practice,
May 1, 2006;
16(3):
263 - 275.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. M. GHARABAWI, C. A. BOSSIE, and Y. ZHU
New-Onset Tardive Dyskinesia in Patients With First-Episode Psychosis Receiving Risperidone or Haloperidol
Am J Psychiatry,
May 1, 2006;
163(5):
938 - 939.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R Bola
Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?
Schizophr Bull,
April 1, 2006;
32(2):
288 - 296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. D. Harvey, J. Rabinowitz, M. Eerdekens, and M. Davidson
Treatment of Cognitive Impairment in Early Psychosis: A Comparison of Risperidone and Haloperidol in a Large Long-Term Trial
Am J Psychiatry,
October 1, 2005;
162(10):
1888 - 1895.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Parellada, R. Andrezina, V. Milanova, P. Glue, M. Masiak, M. St. J. Turner, R. Medori, and W. Gaebel
Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable
J Psychopharmacol,
September 1, 2005;
19(5_suppl):
5 - 14.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. G Robinson, M. G Woerner, H. M Delman, and J. M Kane
Pharmacological Treatments for First-Episode Schizophrenia
Schizophr Bull,
July 1, 2005;
31(3):
705 - 722.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Gardner, R. J. Baldessarini, and P. Waraich
Modern antipsychotic drugs: a critical overview
Can. Med. Assoc. J.,
June 21, 2005;
172(13):
1703 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2005
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
